Our in vivo study showed that the average tumor volume in mice administrated with the combination of HA-PEI/HA-PEG/MDR1 siRNA CD44 targeted nanoparticle and paclitaxel was significantly smaller than that observed in control groups (Fig. 4B). The gene discussed is CD44; the disease is neoplasm.